INTRODUCTION
============

Kawasaki disease (KD) is an acute systemic vasculitis that primarily affects children younger than 5 years of age. There are no specific laboratory tests for the diagnosis of KD; therefore, diagnosis is usually made according to clinical criteria.[@B1] Following Japan, Korea has the second highest prevalence of KD in the world, and the incidence of this disease is increasing steadily.[@B2] Although KD is a self-limiting disease, if not treated properly with intravenous immune globulin (IVIG), coronary artery lesions (CALs) can occur. In developed countries, KD is the most common cause of acquired heart disease.

KD exhibits an epidemic pattern. The peak incidence is at 9−11 months of age, coinciding with waning maternal immunity. Symptoms are similar to those of other infectious diseases, and the course of disease is usually self-limited. For these reasons, KD was once thought to be an infectious disease. Several organisms were reported as causative agents, including viruses and species of some bacteria, such as *Streptococcus* and *Staphylococcus*. However, no causative infectious organisms have been isolated from patients.[@B3]

Genetic predisposition to KD has also been suggested. The annual incidence of KD worldwide is highest and is increasing in Japan, Korea, and Taiwan. This incidence is 10−20 times higher than that of Western countries. Interestingly, the same incidence level in people of Japanese ancestry living in Hawaii indicates that the predilection for Asian populations may not be due solely to geographic factors. KD also exhibits familial disposition. The relative risk for siblings is about 10-fold greater, and a recent study revealed that two-generation KD patients is more prevalent than expected. HLA types and allotypes of immunoglobulin in relation to KD have been studied, although results differ by study and region. Lack of agreement between studies may be due to differences in genetic background among the different races involved. Thus, KD can be thought of as a complex multifactorial disease that develops in association with unidentified infectious organisms in children with a predisposing genetic background.[@B4]

With the recent advent of genome-wide association studies, remarkable progress has been made in identifying candidate genes associated with KD.[@B5] One of the most interesting candidate genes is inositol-1,4,5-triphosphate 3-kinase (*ITPKC*), which was first reported in Japan.[@B6] Different single-nucleotide polymorphisms (SNPs) in the *ITPKC* gene have been reported in several countries.[@B2][@B7] However, a previous study found no polymorphisms in *ITPKC* in Korean KD patients. Interestingly, a recent study reported that polymorphisms in *ITPKC* are associated with reactivation of Bacille Calmette-Guérin (BCG) injection scars.[@B8]

Erythema and induration of the BCG injection site is a specific clinical feature of KD[@B9][@B10] and is present in approximately 30−50% of KD patients, especially in children who are younger than 2 years of age.[@B11][@B12][@B13] Although erythematous changes in the BCG inoculation site in patients with human herpes virus type 6 infection have been reported,[@B14] this clinical feature is known as a specific finding of KD. Chun, et al.[@B15] used BCG in the development of an animal model of KD in programmed death-1 gene knockout mice. These findings suggest a possible correlation between BCG and the pathogenesis of KD.

In inbred mice, resistance and susceptibility to the growth of BCG is controlled by the BCG locus, also known as the natural resistance-associated macrophage protein 1 (*NRAMP1*) gene. The *NRAMP1* gene was later renamed solute carrier 11a1 (*SLC11A1*), and the human homologue was subsequently isolated. Interactions of macrophages with bacterial lipopolysaccharide and/or natural killer cell−or T cell−derived interferon-γ are regulated by *SLC11A1*. Polymorphisms in *SCL11A1* are thought to induce a hypersensitivity reaction to the BCG strain. A relationship between *SCL11A1* polymorphisms and KD has been reported.[@B16]

This study examined polymorphisms in the *ITPCK* gene in Korean patients with KD. Polymorphisms in *SLC11A1* were also examined to determine a possible association with KD. The relationship between KD susceptibility and polymorphisms in these genes was also examined. As other studies have investigated interactions between these two genes, especially with respect to synergistic effects,[@B17][@B18] gene-gene interactions and/or synergistic effects between *SCL11A1* and *ITPKC* polymorphisms in KD were also investigated.

MATERIALS AND METHODS
=====================

Subject groups
--------------

We evaluated 299 patients with typical KD who were admitted to Severance Children\'s Hospital between January 1, 2012 and October 31, 2015. The patients were diagnosed using criteria of the Japanese Kawasaki Disease Research Committee.[@B19] Incomplete or atypical KD cases were excluded. The control group included healthy children who had no past history of KD and had visited the endocrinology clinic of our hospital for cosmetic reasons.

The KD patients were dichotomized based on age: below or over the age of 24 months, since erythema of BCG sites is predominantly observed in children younger than 24 months.

This study was approved by the Institutional Review Board Ethics Committee of Yonsei University College of Medicine (2008-0055-010).

Genomic DNA extraction and whole-gene sequencing
------------------------------------------------

Genomic DNA was extracted using a QIAmp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). DNA was quantified using an Epoch microplate spectrophotometer (BioTek, Winooski, VT, USA).

In order to identify causative variants, we sequenced the *SLC11A1* and *ITPKC* genes in 24 KD patients less than 24 months old who appeared to have BCG injection site erythema. Genomic sequences for analysis were obtained from the GenBank (<https://www.ncbi.nlm.nih.gov/gene/>) database. Polymerase chain reaction (PCR) primers for amplifying the exon and promoter regions (2 kb upstream from exon 1) of the genes were designed using Primer3 software ([http://frodo. wi.mit.edu/primer3/](http://frodo.wi.mit.edu/primer3/)).[@B20] Each amplified PCR fragment was sequenced using BigDye Terminator chemistry on an ABI Prism 3730xl DNA analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s protocol. The results were then expanded to include all KD patients and controls. DNA polymorphisms were identified using the PolyPhred program (<http://droog.gs.washington.edu/polyphred/>).[@B21] Tagging SNPs were selected using Haploview version 4.2. Among SNPs selected according to whole-gene sequencing of *SLC11A1* and *ITPKC* through linkage disequilibrium (LD) analysis, genotyping of tagging SNPs was carried out for all samples using the TaqMan® fluorogenic 5′-nuclease assay (Applied Biosystems). The polymorphism rs2290692 was added in the 3′-UTR of the *ITPKC* gene, as it was recently identified in Han Chinese and is known to be associated with susceptibility to KD.[@B22] Real-time PCR was performed using a QuantStudio™6 Flex Real-Time PCR System (Applied Biosystems). After PCR and genotyping, the data were analyzed using 7500 SDS 2.3 software (Applied Biosystems).

Statistical analysis
--------------------

All statistical analyses were performed using SAS software (version 9.0) on a Windows 7 platform. To test for associations with KD, Cochran-Armitage trend test (chi-squared test) was used to compare allele and genotype frequencies (nominal variables) between cases and controls. Student\'s t-test was used to examine the statistical significance of differences between cases and controls. Binary logistic regression is used to explain the relationship between one dependent binary variable and one or more independent variables (genes). A *p*-value less than 0.05 was considered indicative of statistical significance. Continuous variables are expressed in mean±SD, and categorical variables are expressed in numbers (%).

Synergistic effects between *SLC11A1* and *ITPKC* genetic polymorphisms were analyzed using combination modes of multiple genetic loci. The search for the best combination pattern of the genetic polymorphisms in surveyed genes was carried out based on the principle of maximization of both cross-validation consistency and test balance accuracy in order to evaluate interactions between the two genes of interest in relation to KD.

RESULTS
=======

Clinical characteristics of the subjects
----------------------------------------

A total of 299 KD patients and 210 healthy control children were recruited ([Table 1](#T1){ref-type="table"}). Of the 299 KD patients, 77 (25.75%) patients had BCG injection site erythema. When the subjects were dichotomized by age above or below 24 months, the percentage of patients exhibiting erythema of the BCG site differed (*p*\< 0.001). A total of 62 of 114 (54.39%) younger patients, who were less than 24 months of age, had erythema of the BCG injection site. Among the older subjects, only 15 of 185 (8.11%) exhibited BCG injection site erythema.

KD patients exhibited elevations in white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and lactate dehydrogenase (LDH) level, compared with control participants.

CALs were observed in 55 of 299 patients (18.39%). CALs occurred more frequently (*p*=0.008) in the older age group (42 of 185 patients, 22.70%), compared with the younger age group (13 of 114 patients, 11.40%). 48 patients (16.05%) had recurrence of clinical symptoms. However, there was no difference in recurrence of clinical symptoms between the older age group (30 of 185 patients, 16.22%) and the younger age group (18 of 114 patients, 15.79%).

Polymorphisms of *ITPKC* and *SLC11A1* gene and associations with clinical or laboratory findings
-------------------------------------------------------------------------------------------------

According to the results of preliminary exon sequencing for 24 patients, seven SNPs in *ITPKC* and 10 SNPs in *SLC11A1* were selected. No novel SNPs were identified. Based on the results of LD analyses, four tagging SNPs in *ITPKC* and five tagging SNPs in *SLC11A1* were selected. The frequencies for the entire study group and the control group are listed in [Table 2](#T2){ref-type="table"}.

Comparison of the genotype and allele frequencies in the patient and control groups revealed a significant difference only for rs28493229 in the intron of *ITPKC* (*p*=0.045 and *p*=0.022, respectively). Over-representation of the C allele in rs28493229 of *ITPKC* was observed ([Table 3](#T3){ref-type="table"}). Similar results were observed in the younger patients after dichotomization based on age (*p*=0.039 and *p*=0.031, respectively).

Although no significant difference between the experimental and control groups was observed for rs77624405 in exon 12 of *SLC11A1*, when the patients were dichotomized, a significant difference was found in the younger patients (*p*=0.008 and *p*=0.009, respectively). Overrepresentation of the A allele in rs77624405 of the *SLC11A1* gene was observed ([Table 4](#T4){ref-type="table"}).

The relationship between the identified SNPs and laboratory data was also assessed. The laboratory data differed between the KD patients and normal controls, and the alleles of the related SNPs were heterogeneous.

The rs2290692 polymorphism in *ITPKC* was associated with elevations in WBC, platelet counts, and LDH levels in the KD group, compared with those of the control group. When the KD group was dichotomized based on age above and below 24 months, a different polymorphism pattern was observed. In the younger patients, elevations in WBC count and LDH level were associated with different SNPs, compared with the non-dichotomized KD group. The rs28493229 polymorphism was associated with elevated WBC counts, and the rs10420685 polymorphism was associated with elevated LDH levels in the younger patients. Elevated platelet levels in the younger patients were associated with the same rs28493229 SNP, similar to the non-dichotomized KD group. Elevated ESR was associated with polymorphism rs2290692 in the younger patients, but not in the non-dichotomized KD group. In the older patients, polymorphism rs2290692 was associated with elevated WBC counts, similar to the non-dichotomized KD group. Polymorphism rs28493229 was associated with elevated platelet counts in the older patients, a pattern that differed compared with that of the non-dichotomized KD group and younger patients.

Polymorphism of rs17235409 in *SLC111A1* was associated with elevated LDH in the older age group, and polymorphism of rs2276631 in *SLC11A1* was associated with increased aspartate aminotransferase levels in the younger age group. Besides these two polymorphisms of *SLC11A1*, no SNP sites in *SLC11A1* were related with inflammatory markers ([Table 5](#T5){ref-type="table"}).

Interactions between the *ITPKC* and *SLC11A1* genes in KD patients
-------------------------------------------------------------------

When comparing the KD patients and controls, no significant interactions between the *ITPKC* and *SLC11A1* genes were observed. However, after the KD patients were dichotomized based on age above and below 24 months, interactions between *ITPKC* rs2561531 CC and *SLC11A1* rs17221959 CT and between *ITPKC* rs2561531 CC and *SLC11A1* rs77624405 GA appeared to exert a protective effect against KD symptoms in the younger patients ([Table 6](#T6){ref-type="table"}).

Associations of polymorphisms in the *ITPKC* and *SLC11A1* genes with BCG injection site erythema
-------------------------------------------------------------------------------------------------

No SNPs exhibiting a relationship with BCG injection site erythema were found in *ITPKC* in the KD group. Polymorphism rs17235409 in *SLC11A1* exhibited a relationship with BCG injection site erythema only in the younger-age KD patients ([Table 7](#T7){ref-type="table"}).

Association of *ITPKC* and *SLC11A1* gene interactions with BCG injection site erythema in KD patients
------------------------------------------------------------------------------------------------------

As shown in [Table 8](#T8){ref-type="table"}, statistically significant associations were found for interactions between rs28493229 of *ITPKC* and rs17235409 of *SLC11A1* \[odds ratio (OR)=5.1; *p*=0.017\] and between rs10420685 of *ITPKC* and rs7235409 of *SLC11A1* (OR=12.51; *p*=0.008) in the older-age KD patients.

Associations of polymorphisms in the *ITPKC* and *SLC11A1* genes with CALs and clinical symptom recurrence
----------------------------------------------------------------------------------------------------------

As shown in [Table 9](#T9){ref-type="table"}, polymorphism rs28493229 in *ITPKC* was associated with CALs. However, no *ITPKC* or *SLC11A1* SNPs were found to be associated with the recurrence of clinical symptoms.

DISCUSSION
==========

The KD-associated gene *ITPKC* was first identified and studied in Japan.[@B6] Many studies have shown relatively higher frequencies of *ITPKC* in Japanese (0.16) and European populations (0.15), compared with Taiwanese populations (0.054).[@B7] Consistent with geographic differences in SNPs, one study conducted in Korea did not find similar polymorphisms in *ITPKC*.[@B23] In the present study, KD was carefully classified and an appropriate control group was selected to ensure the validity of the results. Patients with atypical or incomplete KD were thus excluded, as were those treated with IVIG before the fourth day of fever. In the present study, a significant increase in the frequency of allele C in rs28493229 was found in KD patients overall. The same increase was observed in KD patients younger than 24 months. Contrary to previous reports from Korea, this result demonstrated that polymorphisms in *ITPKC* are indeed associated with KD in Korea. However, the frequency was low (0.12), compared with that reported for other countries, including Japan (0.16).[@B7]

rs28493229 polymorphism in *ITPKC* was also significantly associated with CALs. In our study, only genotype showed a statistically significant difference but not in alleles. Onouchi[@B7] reported a significant relationship between the C allele and CALs. In the present study, however, the frequency of the C allele was higher in CALs, although no statistically significant difference was found. In contrast, the same SNP in Taiwanese children was not significantly associated with CALs. These results provide some explanation for the variety of country-specific SNPs.[@B8][@B24]

A number of inflammatory markers, such as ESR, CRP, WBC, platelets, and LDH, are typically elevated in the peripheral blood of KD patients during the acute phase of the disease. The patients in the present study also exhibited increased WBC and platelet counts, as well as elevated LDH, CRP levels, and ESR levels. A previous study reported no significant correlations between SNPs in *ITPKC* and various inflammatory markers.[@B8] In the present study, however, several polymorphisms in *ITPKC* and *SLC11A1* were associated with elevations in WBC and platelet counts, as well as LDH levels, in the KD group relative to the controls, as shown in [Table 5](#T5){ref-type="table"}. The association with elevated inflammatory markers was more pronounced for polymorphisms in *SLC11A1*, compared with those in *ITPKC*. Furthermore, this association differed in older and younger patients.

The results of this study suggest that KD is not a single disease entity. Differences in age of onset, clinical feature, pattern of laboratory data, and response to IVIG treatment in conjunction with age-related differences in SNPs suggest that KD would be more appropriately designated Kawasaki 'syndrome', as it more closely resembles a group of heterogeneous entities that present a similar clinical picture.

A typical laboratory finding in KD is elevated platelet counts. This is very important, because low-dose aspirin treatment is used to prevent thrombosis associated with elevations in platelet count. The exact mechanism underlying the development of thrombocytosis in KD is unknown. Speculatively an increase in serum interleukin (IL)-6 levels during the acute phase of the disease triggers megakaryocyte maturation in the bone marrow, resulting in an increase in the number of platelets in the peripheral blood.[@B25] According to our data, SNPs in *ITPKC* (but not *SLC11A1*) are associated with thrombocytosis. These results indicate that *ITPKC* is more closely associated with inflammation in KD than *SLC11A1*.

Another interesting finding of the present study is that poly-morphism rs28493229 in *ITPKC* has a protective effect against KD symptoms \[OR 0.563; 95% confidence interval (CI) 0.343− 0.923; *p*=0.022\]. We expected that the most-studied *ITPKC* SNP rs28493229 would instead have a triggering effect on KD.[@B26] Some studies have shown no association between KD and polymorphism rs28493229 in *ITPKC*.[@B27] However, the opposite effect was observed in the present study. Along with the previously mentioned increases in many inflammatory cytokines during the acute phase of KD, there is a simultaneous increase in the production of the anti-inflammatory cytokine IL-10.[@B5][@B26][@B28] A number of systems within the human body contribute to the maintenance of homeostasis. When inflammation in the body arises, anti-inflammatory processes work simultaneously to restore homeostasis. Considering this context, the rs28493229 polymorphism in *ITPKC* may play a role in suppressing the initial symptoms of KD as a means of maintaining homeostasis.

In the process of choosing tagging SNPs, we added rs2290692 in the 3′-UTR of *ITPKC*. Han Chinese KD patients have a higher frequencies of the C allele (*p*\<0.001), compared with disease-free participants.[@B22] However, no statistically significant difference in C-allele frequency between KD patients and controls was observed in the present study. This result further demonstrates the geographic differences in the genetic background of KD.

The *SLC11A1* gene was originally named *NRAMP1*. *SLC11A1* encodes an iron-transporting protein that plays an important role in controlling susceptibility to *Mycobacterium tuberculosis* infection via regulation of IL-1 and TNF production, as well as the activation of macrophages. With respect to BCG, it identifies host genes and proteins that play a key role in the response to mycobacterial infections.[@B29] As BCG injection site erythema is most common in younger KD patients, we searched for polymorphisms in this gene and found a total of 15 SNPs. Ouchi, et al.[@B16] showed that one variant of the *SLC11A1* gene is associated with KD in Japan. However, they could not find any polymorphisms in the *SLC11A1* gene, perhaps due to the age of the KD patients enrolled in the study. In contrast to Ouchi, et al.,[@B16] who did not consider the age of patients in their analysis, in our study, KD patients were dichotomized based on age less than and more than 24 months. In comparing the KD group as a whole with controls, no polymorphisms in *SLC11A1* were found, in agreement with the study of Ouchi, et al.[@B16] However, when KD patients under 24 months of age were considered, a statistically significant polymorphism, rs77624405, was identified, suggesting that this polymorphism in *SLC11A1* is associated with KD in patients under 24 months of age. This finding correlates well with the observed frequency of BCG injection site erythema in patients under 24 months of age. Compared with control subjects, KD patients under 24 months of age tended to have a higher frequency of the A allele in rs2276631, whereas KD patients over 24 months of age tended to have a higher frequency of the A allele in rs17235409.

Gene-gene interactions have been linked to a number of important diseases, such as diabetes and essential hypertension.[@B30][@B31] In KD, interactions between *ITPKC* and the caspase-3 gene have been studied with respect to an association between unresponsiveness of IVIG and development of coronary artery complications.[@B32][@B33] The potential role of interactions between *ITPKC* and *SLC11A1* was therefore examined in the present study. No meaningful interactions between these two genes were observed when the overall KD and control groups were analyzed. However, interactions between rs2561531 in *ITPKC* and rs17221959 in *SLC11A1* and between rs2561531 in *ITPKC* and rs77624405 in *SLC11A1* were found when the KD patients were considered based on age above and below 24 months, and these interactions were found to have a protective effect. The rs2561531 polymorphism in *ITPKC* is particularly interesting. This SNP was not identified in analyses of *ITPKC* in the KD patients. In analyses of potential associations between *ITPKC* and *SLC11A1*, however, a role for rs2561531 in *ITPKC* was revealed. Roles for rs17221959 and rs77624405 in *SLC11A1* were also identified.

Although BCG injection site erythema is not included in the diagnostic criteria for KD, it is an important clue, as there is no other disease associated with erythematous changes at the BCG injection site. In a previous report, Lin, et al.[@B8] concluded that there is an association between the C allele of *ITPKC* SNP rs28493229 and BCG scars, although the frequency is low (8.04%). However, in the present study, the C allele of *ITPKC* SNP rs28493229 was not significantly associated with BCG injection site erythema.

In younger KD patients, the *SLC11A1* SNP rs17235409 was associated with BCG injection site erythema. Although one Japanese study reported no polymorphisms in *SLC11A1*,[@B16] the results may have been affected by differences in nationality, year of introduction of BCG vaccination, or BCG coverage rate. A comparison of patients of all ages with and without BCG injection site erythema indicated that *SLC11A1* SNP rs2276631 was associated with a decreased risk of KD (OR 0.161; 95% CI 0.038−0.689; *p*=0.014). In patients less than 24 months of age, however, the *SLC11A1* SNP rs17235409 was associated with increased risk of KD (OR 2.483; 95% CI 1.063−5.804; *p*=0.036).

The *SLC11A1* gene is known to be associated with autoimmune and infectious diseases. The SNPs analyzed in this study are associated more with infectious than autoimmune disease. The SNPs rs7573065, rs2276631, rs17221959, and rs17235409 in *SLC11A1* are associated with tuberculosis and infection with *Mycobacterium spp*., with one meta-analysis reporting estimated OR \>1.[@B34] As BCG immunization is given to children at less than 1 month of age, the association of these SNPs with KD may be more significant in younger children.

Analyses of interactions between *ITPKC* and *SLC11A1* showed a synergistic effect for BCG injection site erythema in patients over 24 months of age. Interactions between rs28493229 in *IT-PKC* and rs17235409 in *SLC11A1* and between rs10420685 in *ITPKC* and rs7235409 in *SLC11A1* may trigger erythema in BCG injection sites. These results indicate that reactivation of BCG scars is associated with polymorphisms in either *ITPKC* or *SLC11A1* in patients under 24 months of age. However, in patients older than 24 months, reactivation of BCG scars is associated with synergism between the polymorphisms of these two genes rather than either of the genes alone.

During the acute phase of KD, striking immunological derangements occur, including changes in immune cells and marked inflammatory cytokine cascade stimulation.[@B3] In light of these changes, Kim[@B3] suggested that acquired immune responses play an important role in the development of KD. Recently, Ikeda, et al.[@B35] suggested that innate immunity, rather than acquired immunity, plays an important role in the development of vasculitis in KD. Kusuda, et al.[@B36] reported that KD-specific molecules in the serum possess structures common to microbe-associated molecular pattern (MAMP) molecules of bacteria, such as *Bacillus*, *Yersinia*, and *Staphylococcus*, and that levels of these molecules decline after IVIG treatment. Hara[@B37] suggested that increased levels of MAMP and damage-associated molecular pattern (DAMP) molecules in the serum of acute-phase KD patients activate the immune system and vascular cells through innate immune pattern recognition receptors, leading to the release of various cytokines. Heat shock protein, which is contained in considerable amounts in the BCG vaccine, is a well-known DAMP. It can thus be speculated that BCG-associated DAMPs play an important role in the development of KD.

Many researchers have concluded that the innate immune system is present at birth and does not change throughout one\'s life.[@B38] However, the results of the present study indicate that KD is associated with a difference in genetic background with respect to various inflammatory markers and reactivation of BCG scars in patients younger and older than 24 months. Interestingly, increasing evidence indicates that there are age-associated differences in the maturation and function of the innate immune system.[@B39][@B40] In light of these factors, the results of the present study show that age-associated differences in BCG injection site erythema and genetic background in patients with KD are reasonable.

It is unclear whether BCG itself induces KD or the BCG injection site is reactivated as a result of specific processes that occur during initiation of KD or possibly whether reactivation of the BCG injection site is caused by the suppression of the inflammation process in KD. Nevertheless, it is clear that the BCG injection site exhibits inflammatory changes that manifest as erythema. Further study is needed to clarify the relationship between BCG injection site erythema and KD, as demonstrated by Chun, et al.[@B15]

This study has several limitations. First, the study was not conducted at the functional gene level. Second, the power of the study was low. Third, the control group was not age-matched. However, it was concluded that age matching would not significantly impact the results, as future development of KD in young, healthy children cannot be ruled out. Therefore, older patients without a history of KD were considered a better choice for the control group.

In conclusion, this study identified polymorphisms in the *ITPKC* and *SLC11A1* genes in Korean KD patients. These polymorphisms were associated with increased production of inflammatory markers in the peripheral blood of patients with KD. The SNPs identified in this study were also associated with erythema of the BCG injection site in KD patients, although their effects differed depending on age of patients.

The authors have no financial conflicts of interest.

###### Characteristics of the Study Subjects

![](ymj-59-119-i001)

  Variables                         KD patients        Controls (n=210)        *p* value                                 
  --------------------------------- ------------------ ----------------------- ------------------------ ---------------- --------------
  Age (month)                       41.81±39.49        11.81±5.88              60.33±40.05              115.97±35.24     \<0.0001^\*^
  Gender (M:F)                      194:105            81 (41.8%):33 (31.4%)   113 (58.2%):72 (68.6%)   130:80           \<0.0001^\*^
  BCG injection site erythema (%)   77                 62 (80.5)               15 (19.5)                NA               \<0.001^†^
  WBC                               12900.73±5315.07   13594.09±5195.91        12432.82±5359.14         6910.71±201.68   \<0.0001^\*^
  Platelet                          399.97±182.73      425.72±181.55           382.60±182.02            304.70±71.17     \<0.0001^\*^
  ESR                               63.51±32.49        59.93±33.15             65.98±31.90              11.00±9.81       \<0.0001^\*^
  CRP                               57.75±53.02        51.09±47.92             62.33±55.95              9.152±14.61      0.069^\*^
  LDH                               334.75±145.66      334.06±115.38           335.21±163.21            241.21±41.67     \<0.0001^\*^
  Coronary complication (%)         55                 13 (23.6)               42 (76.4)                NA               0.008^†^
  Recur of KD (%)                   48                 18 (37.5)               30 (62.5)                NA               0.296^†^

KD, Kawasaki disease; BCG, Bacille Calmette-Guérin; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase.

^\*^*p* value for comparison between KD patients and controls, ^†^*p* value for comparison between \<24-month-old KD patients (younger age group) and ≥24-monthold KD patients (older age group).

###### Frequency of SNPs in the *ITPKC* and *SLC11A1* Genes for the Patient and Control Groups

![](ymj-59-119-i002)

  Variations (SNPs)   Genotypes     *p* value     Alleles      *p* value                                               
  ------------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------- -------
  *ITPKC*                           CC            CT           TT                          C             T             
   rs2561531          Controls      130 (61.90)   70 (33.33)   10 (4.76)     0.957         330 (78.57)   90 (21.43)    0.856
  KD patients         184 (61.54)   99 (33.11)    16 (5.35)    467 (78.09)   131 (21.91)                               
                                    GG            GC           CC                          G             C             
   rs28493229         Controls      178 (84.76)   32 (15.24)   0 (0.00)      0.045         388 (92.38)   32 (7.62)     0.022
  KD patients         231 (77.26)   64 (21.40)    4 (1.34)     526 (87.96)   72 (12.04)                                
                                    AA            AG           GG                          A             G             
   rs10420685         Controls      114 (54.29)   76 (36.19)   20 (9.52)     0.836         304 (72.38)   116 (27.62)   0.777
  KD patients         156 (52.17)   116 (38.80)   27 (9.03)    428 (71.57)   170 (28.43)                               
                                    GG            GC           CC                          G             C             
   rs2290692          Controls      65 (30.95)    97 (46.19)   48 (22.86)    0.933         227 (54.05)   193 (45.95)   0.908
  KD patients         89 (29.77)    143 (47.83)   67 (22.41)   321 (53.68)   277 (46.32)                               
  *SLC11A1*                         CC            CT           TT                          C             T             
   rs7573065          Controls      194 (92.38)   15 (7.14)    1 (0.48)      0.405         403 (95.95)   17 (4.05)     0.815
  KD patients         273 (91.30)   26 (8.70)     0 (0.00)     572 (95.65)   26 (4.35)                                 
                                    GG            GA           AA                          G             A             
   rs2276631          Controls      143 (68.10)   59 (28.10)   8 (3.81)      0.909         345 (82.14)   75 (17.86)    0.688
  KD patients         209 (69.90)   79 (26.42)    11 (3.68)    497 (83.11)   101 (16.89)                               
                                    CC            CT           TT                          C             T             
   r17221959          Controls      186 (88.57)   24 (11.43)   0 (0.00)      0.202         396 (94.29)   24 (5.71)     0.220
  KD patients         253 (84.62)   46 (15.38)    0 (0.00)     552 (92.31)   46 (7.69)                                 
                                    GG            GA           AA                          G             A             
   rs77624405         Controls      204 (97.14)   6 (2.86)     0 (0.00)      0.072         414 (98.57)   6 (1.43)      0.076
  KD patients         280 (93.65)   19 (6.35)     0 (0.00)     579 (96.82)   19 (3.18)                                 
                                    GG            GA           AA                          G             A             
   rs17235409         Controls      165 (78.57)   42 (20.00)   3 (1.43)      0.886         372 (88.57)   48 (11.43)    0.780
  KD patients         239 (79.93)   55 (18.39)    5 (1.67)     533 (89.13)   65 (10.87)                                

SNPs, single nucleotide polymorphisms; *ITPKC*, inositol 1,4,5-triphosphate 3-kinase; *SLC11A1*, solute carrier 11a1; KD, Kawasaki disease.

###### Frequencies of *ITPKC* rs28493229

![](ymj-59-119-i003)

  Phenotype     Genotypes     *p* value     Alleles      *p* value                                            
  ------------- ------------- ------------- ------------ ------------- ------------ ------------- ----------- -------
  All           Controls      178 (84.76)   32 (15.24)   0 (0.00)      0.045        388 (92.38)   32 (7.62)   0.022
  KD patients   231 (77.26)   64 (21.40)    4 (1.34)     526 (87.96)   72 (12.04)                             
  \<24 months   Controls      178 (84.76)   32 (15.24)   0 (0.00)      0.039        388 (92.38)   32 (7.62)   0.031
  KD patients   86 (75.44)    27 (23.68)    1 (0.88)     199 (87.28)   29 (12.71)                             
  ≥24 months    Controls      178 (84.76)   32 (15.24)   0 (0.00)      0.065        388 (92.38)   32 (7.62)   0.052
  KD patients   145 (78.38)   37 (20.00)    3 (1.62)     327 (88.38)   43 (11.62)                             

*ITPKC*, inositol 1,4,5-triphosphate 3-kinase; KD, Kawasaki disease.

###### Frequencies of *SLC11A1* rs77624405

![](ymj-59-119-i004)

  Phenotype     Genotypes     *p* value     Alleles       *p* value                            
  ------------- ------------- ------------- ------------- ----------- ------------- ---------- -------
  All           Controls      204 (97.14)   6 (2.86)      0.072       414 (98.57)   6 (1.43)   0.076
  KD patients   280 (93.65)   19 (6.35)     579 (96.82)   19 (3.18)                            
  \<24 months   Controls      204 (97.14)   6 (2.86)      0.008       414 (98.57)   6 (1.43)   0.009
  KD patients   103 (90.35)   11 (9.65)     217 (95.18)   11 (4.82)                            
  ≥24 months    Controls      204 (97.14)   6 (2.86)      0.425       414 (98.57)   6 (1.43)   0.429
  KD patients   177 (95.68)   8 (4.32)      362 (97.84)   8 (2.16)                             

*SLC11A1*, solute carrier 11a1; KD, Kawasaki disease.

###### Association between Laboratory Data and Polymorphisms in the *ITPKC* and *SLC11A1* Genes

![](ymj-59-119-i005)

  Phenotype                   SNP                     Values             *p* value
  --------------------------- ----------------------- ------------------ -----------
  *ITPKC* gene                                                           
   KD vs. control             rs2290692_GC            Elevation of WBC   0.021
  rs2290692_GC                Elevation of platelet   0.024              
  rs2290692_CC                Elevation of LDH        0.040              
   \<24 months vs. controls   rs28493229_CC           Elevation of WBC   \<0.001
  rs2290692_GC                Elevation of platelet   0.046              
  rs2290692_GC                Elevation of ESR        0.025              
  rs10420685_AG               Elevation of LDH        0.014              
   ≥24 months vs. controls    rs2290692_GC            Elevation of WBC   0.033
  rs28493229_CC               Elevation of platelet   0.008              
  *SLC11A1* gene                                                         
   \<24 months vs. controls   rs2276631_GA            Elevation of AST   0.022
   ≥24 months vs. controls    rs17235409_GA           Elevation of LDH   0.050

*ITPKC*, inositol 1,4,5-triphosphate 3-kinase; *SLC11A1*, solute carrier 11a1; SNPs, single nucleotide polymorphisms; KD, Kawasaki disease; WBC, white blood cell; LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransferase

###### Gene-Gene Interactions between the *ITPKC* and *SLC11A1* Genes in KD Patients

![](ymj-59-119-i006)

  Phenotype/genotype      OR (95% CI)               *p* value              
  ----------------------- ------------------------- ---------------------- -------
  All                                                                      
   *ITPKC* rs2561531_CC   *SLC11A1* rs17221959_CT   0.841 (0.387--1.828)   0.661
   *ITPKC* rs2561531_CC   *SLC11A1* rs77624405_GA   0.249 (0.047--1.328)   0.104
  \<24 months                                                              
   *ITPKC* rs2561531_CC   *SLC11A1* rs17221959_CT   0.379 (0.154--0.931)   0.034
   *ITPKC* rs2561531_CC   *SLC11A1* rs77624405_GA   0.128 (0.025--0.667)   0.015

*ITPKC*, inositol 1,4,5-triphosphate 3-kinase; *SLC11A1*, solute carrier 11a1; KD, Kawasaki disease; OR, odds ratio; CI, confidence interval.

###### Association of the rs17235409 Polymorphism in *SLC11A1* with BCG Injection Site Erythema

![](ymj-59-119-i007)

  Genotypes     BCG (+)       Control       *p* value
  ------------- ------------- ------------- -----------
  All                                       
   GG           62 (80.52)    155 (78.68)   0.900
   GA           14 (18.18)    38 (19.29)    
   AA           1 (1.30)      4 (2.03)      
   G            138 (89.61)   348 (88.32)   0.669
   A            16 (10.39)    46 (11.68)    
  \<24 months                               
   GG           53 (85.48)    32 (66.67)    0.037
   GA           8 (12.90)     15 (31.25)    
   AA           1 (1.61)      1 (2.08)      
   G            114 (91.94)   79 (82.29)    0.031
   A            10 (8.06)     17 (17.71)    

*SLC11A1*, solute carrier 11a1; BCG, Bacille Calmette-Guérin.

###### Gene-Gene Interactions of *ITPKC* and *SLC11A1* Genes with BCG Injection Site Erythema

![](ymj-59-119-i008)

  Phenotype/genotype       OR (95% CI)               *p* value                        
  ------------------------ ------------------------- -------------------------------- -------
  All                                                                                 
   *ITPKC* rs28493229_GG   *SLC11A1* rs17235409_GA   0.031 (0.093−1.031)              0.056
   *ITPKC* rs10420685_GG   *SLC11A1* rs17235409_AA   \<0.001 (\<0.001 -- \<999.999)   0.985
  ≥24 months                                                                          
   *ITPKC* rs28493229_GG   *SLC11A1* rs17235409_GA   5.105 (1.345--19.372)            0.017
   *ITPKC* rs10420685_GG   *SLC11A1* rs17235409_AA   12.51 (1.927--82.01)             0.008

*ITPKC*, inositol 1,4,5-triphosphate 3-kinase; *SLC11A1*, solute carrier 11a1; BCG, Bacille Calmette-Guérin; OR, odds ratio; CI, confidence interval.

###### Relationship between the *ITPKC* Polymorphism rs28493229 and CALs

![](ymj-59-119-i009)

  Phenotype          Genotypes     *p* value    Alleles    *p* value                              
  ------------------ ------------- ------------ ---------- ----------- ------------- ------------ -------
  All                                                      0.043                                  0.087
   No CAL patients   181 (78.35)   49 (21.21)   1 (0.43)               411 (88.96)   51 (11.04)   
   CAL patients      40 (72.73)    12 (21.82)   3 (5.45)               92 (83.64)    18 (16.36)   

*ITPKC*, inositol 1,4,5-triphosphate 3-kinase; CAL, coronary artery lesion.
